Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet. Oncol. 13, 239–246 (2012).
Mayor, S. Osimertinib effective in EGFR T790M-positive lung cancer. Lancet. Oncol. 18, e9 (2017).
Recondo, G., Che, J., Jänne, P. A. & Awad, M. M. Targeting MET Dysregulation in Cancer. Cancer Discov. 10, 922–934 (2020).
Guo, R. et al. MET-dependent solid tumours – molecular diagnosis and targeted therapy. Nat. Rev. Clin. Oncol. 17, 569–587 (2020).
Paik, P. K. et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N. Engl. J. Med. 383, 931–943 (2020).
Wolf, J. et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N. Engl. J. Med. 383, 944–957 (2020).
Lu, S. et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet. Respir. Med. 9, 1154–1164 (2021).
Moro-Sibilot, D. et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann. Oncol. 30, 1985–1991 (2019).
Landi, L. et al. Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clin. Cancer Res. 25, 7312–7319 (2019).
Schuler, M. H. et al. Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC). J. Clin. Oncol. 34, 9067–9067 (2016).
Wu, Y. L. et al. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. J. Clin. Oncol. 36, 3101–3109 (2018).
Li, A. N., Yang, J.-J., Zhang, X.-C. & Wu, Y.-L. Crizotinib in advanced non-small-cell lung cancer with de novo c-Met overexpression. J. Clin. Oncol. 33, 8090–8090 (2015).
Bubendorf, L. et al. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer 111, 143–149 (2017).
Reis, H. et al. MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. Clin. Lung Cancer 19, e441–e463 (2018).
Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453–457 (2017).
Boumahdi, S. & de Sauvage, F. J. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov 19, 39–56 (2020).
Qin, S. et al. Emerging role of tumor cell plasticity in modifying therapeutic response. Signal. Transduct. Target Ther. 5, 228 (2020).
Yuan, S., Norgard, R. J. & Stanger, B. Z. Cellular Plasticity in Cancer. Cancer Discov. 9, 837–851 (2019).
Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611 (2017).
Attila, M., Jürgen, R. & Victor, L. J. T. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10, 387 (2010).
Geahlen, R. L. Getting Syk: spleen tyrosine kinase as a therapeutic target. Trend. Pharmacol. Sci. 35, 414–422 (2014).
Yauch, R. L. et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 11, 8686–8698 (2005).
Rho, J. K. et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63, 219–226 (2009).
Byers, L. A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279–290 (2013).
Weng, C. H. et al. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene 38, 455–468 (2019).
Chung, J. H. et al. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer 73, 176–182 (2011).
Seashore-Ludlow, B. et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discov. 5, 1210–1223 (2015).
Taube, J. H. et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. USA 107, 15449–15454 (2010).
Gröger, C. J., Grubinger, M., Waldhör, T., Vierlinger, K. & Mikulits, W. Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS One 7, e51136 (2012).
Mak, M. P. et al. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin. Cancer Res. 22, 609–620 (2016).
Hänzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).
Sonnylal, S. et al. Connective tissue growth factor causes EMT-like cell fate changes in vivo and in vitro. J. Cell Sci. 126, 2164–2175 (2013).
Zhang, F. et al. Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors. Cell Res. 32, 1047–1067 (2022).
Pastushenko, I. et al. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature 589, 448–455 (2021).
Wang, L., Devarajan, E., He, J., Reddy, S. P. & Dai, J. L. Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res. 65, 10289–10297 (2005).
Obenauf, A. C. et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520, 368–372 (2015).
Shen, A. et al. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res. 75, 4548–4559 (2015).
Costa, D. B. et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 4, 1669–1679 (2007). discussion 1680.
Arthur, H. M. & Dijke, P. T. Extracellular control of TGFβ signalling in vascular development and disease. Nat. Rev. Mol. Cell Biol. 8, 857–869 (2007).
Pignatelli, J., Tumbarello, D. A., Schmidt, R. P. & Turner, C. E. Hic-5 promotes invadopodia formation and invasion during TGF-beta-induced epithelial-mesenchymal transition. J. Cell Biol. 197, 421–437 (2012).
Ai, J. et al. Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models. Mol. Cancer Ther. 17, 751–762 (2018).
Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. EMT: 2016. Cell 166, 21–45 (2016).
Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).
Guo, R. et al. MET inhibitor resistance in patients with MET exon 14-altered lung cancers. J. Clin. Oncol 37, 9006–9006 (2019).
Fujino, T. et al. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. J. Hematol. Oncol. 15, 79 (2022).
Fujino, T. et al. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. J. Thorac. Oncol. 14, 1753–1765 (2019).
Engstrom, L. D. et al. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. Clin. Cancer Res. 23, 6661–6672 (2017).
Jin, W. et al. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping. J. Thorac. Onco.l 14, e137–e139 (2019).
Dong, H. J. et al. Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations. Lung Cancer 102, 118–121 (2016).
Heist, R. S. et al. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J. Thorac. Oncol. 11, 1242–1245 (2016).
Ou, S. I. et al. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. J. Thorac. Oncol. 12, 137–140 (2017).
Schrock, A. B., Lai, A., Ali, S. M., Miller, V. A. & Raez, L. E. Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping. J. Thorac. Oncol. 12, e89–e90 (2017).
Rotow, J. K. et al. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin. Cancer Res. 26, 439–449 (2020).
Suzawa, K. et al. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clin. Cancer Res. 25, 1248–1260 (2019).
Recondo, G. et al. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clin. Cancer Res. 26, 2615–2625 (2020).
Riedel, R. et al. FP14.04 Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors. J. Thorac. Oncol. 16, S228 (2021).
Bahcall, M. et al. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. Clin. Cancer Res. 24, 5963–5976 (2018).
Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44, 852–860 (2012).
Byers, L. A. et al. Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update. J. Clin. Oncol. 39, 9110–9110 (2021).
Kaimori, A. et al. Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J. Biol. Chem. 282, 22089–22101 (2007).
Yook, J. I., Li, X. Y., Ota, I., Fearon, E. R. & Weiss, S. J. Wnt-dependent regulation of the E-cadherin repressor snail. J. Biol. Chem. 280, 11740–11748 (2005).
Rastogi, I. et al. Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer. Biochem. Biophys. Res. Commun. 477, 937–944 (2016).
Koeppen, H. et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin. Cancer Res. 20, 4488–4498 (2014).
Li, J. H. et al. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. Faseb j 18, 176–178 (2004).
Zhong, F. J. et al. STMN2 mediates nuclear translocation of Smad2/3 and enhances TGFβ signaling by destabilizing microtubules to promote epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett. 506, 128–141 (2021).
Tan, A. C. & Tan, D. S. W. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J. Clin. Oncol. 40, 611–625 (2022).
Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).